Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 7, 2012, Pages 836-843

  Salama, Mohamed ^a   Ellaithy, Amr ^a   Helmy, Basem ^a   El Gamal, Mohamed ^a   Tantawy, Dina ^a   Mohamed, Mie ^a   Sheashaa, Hussein ^b   Sobh, Mohamed ^a,b   Arias Carrión, Oscar ^c  

^a MANSOURA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

^c HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

Author keywords

Anti apoptotic; Colchicine; Neuroprotection; Parkinson's disease; Rotenone

Indexed keywords

CARBOXYMETHYLCELLULOSE; COLCHICINE; ROTENONE;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY POSTURE; CATALEPSY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MOTOR PERFORMANCE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; RAT; REARING; TREMOR;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; CATALEPSY; COLCHICINE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; DYSKINESIAS; INJECTIONS, INTRAPERITONEAL; LOCOMOTION; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; ROTENONE; SUBSTANTIA NIGRA; TREMOR; TUBULIN MODULATORS; TYROSINE 3-MONOOXYGENASE;

EID: 84873034742     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527311201070836     Document Type: Article

References (45)

1. Salama, M.; Arias-Carrion, O. Natural toxins implicated in the development of Parkinson's disease. Ther. Adv. Neurol. Disord., 2011, 4, 361-373.
2. Depboylu, C.; Schafer, M.K.; Arias-Carrion, O.; Oertel, W.H.; Weihe, E.; Höglinger, G.U. Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease. J. Neuropathol. Exp. Neurol., 2011, 70, 125-132.
3. Arias-Carrion, O.; Stamelou, M.; Murillo-Rodriguez, E.; Menendez-Gonzalez, M.; Poppel, E. Dopaminergic reward system: a short integrative review. Int. Arch. Med., 2010, 3, 24.
4. Surmeier, D.J.; Guzman, J.N.; Sanchez-Padilla, J.; Goldberg, J.A. What causes the death of dopaminergic neurons in Parkinson's disease? Prog. Brain Res., 2010, 183, 59-77.
5. Obeso, J.A.; Rodriguez-Oroz, M.C.; Goetz, C.G.; Marin, C.; Kordower, J.H.; Rodriguez, M.; Hirsch, E.C.; Farrer, M.; Schapira, A.H.; Halliday, G. Missing pieces in the Parkinson's disease puzzle. Nat. Med., 2010, 16, 653-661.
6. Schapira, A.H.; Jenner, P. Etiology and pathogenesis of Parkinson's disease. Mov. Disord., 2011, 26, 1049-1055.
7. Sulzer, D.; Surmeier, D.J. Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov. Disord., 2012.
8. Schulz, J.B. Mechanisms of neurodegeneration in idiopathic Parkinson's disease. Parkinsonism Relat. Disord., 2007, 13 Suppl 3, S306-S308.
9. Glass, C.K.; Saijo, K.; Winner, B.; Marchetto, M.C.; Gage, F.H. Mechanisms underlying inflammation in neurodegeneration. Cell, 2010, 140, 918-934.
10. Jenner, P. Oxidative stress in Parkinson's disease. Ann. Neurol., 2003, 53 Suppl 3, S26-S36; discussion S36-S38.
11. Anglade, P.; Vyas, S.; Javoy-Agid, F.; Herrero, M.T.; Michel, P.P.; Marquez, J.; Mouatt-Prigent, A.; Ruberg, M.; Hirsch, E.C.; Agid, Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol., 1997, 12, 25-31.
12. Hoglinger, G.U.; Breunig, J.J.; Depboylu, C.; Rouaux, C.; Michel, P.P.; Alvarez-Fischer, D.; Boutillier, A.L.; Degregori, J.; Oertel, W.H.; Rakic, P.; Hirsch, E.C.; Hunot, S. The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc. Natl. Acad. Sci. USA, 2007, 104, 3585-3590.
13. Terkeltaub, R.A. Colchicine update: 2008. Semin. Arthritis Rheum., 2009, 38, 411-419.
14. Kesselheim, A.S.; Solomon, D.H. Incentives for drug development-the curious case of colchicine. N. Engl. J. Med., 2010, 362, 2045-2047.
15. Ben-Chetrit, E.; Bergmann, S.; Sood, R. Mechanism of the antiinflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis. Rheumatology (Oxford), 2006, 45, 274-282.
16. Ben-Chetrit, E.; Levy, M. Colchicine: 1998 update. Semin. Arthritis Rheum., 1998, 28, 48-59.
17. Burns, R.G. Analysis of the colchicine-binding site of beta-tubulin. FEBS Lett., 1992, 297, 205-208.
18. Dumortier, C.; Gorbunoff, M.J.; Andreu, J.M.; Engelborghs, Y. Different kinetic pathways of the binding of two biphenyl analogues of colchicine to tubulin. Biochemistry, 1996, 35, 4387-4395.
19. Cronstein, B.N.; Molad, Y.; Reibman, J.; Balakhane, E.; Levin, R.I.; Weissmann, G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J. Clin. Invest., 1995, 96, 994-1002.
20. Modriansky, M.; Tyurina, Y.Y.; Tyurin, V.A.; Matsura, T.; Shvedova, A.A.; Yalowich, J.C.; Kagan, V.E. Anti-/pro-oxidant effects of phenolic compounds in cells: are colchicine metabolites chain-breaking antioxidants? Toxicology, 2002, 177, 105-117.
21. Feng, G.; Kaplowitz, N. Colchicine protects mice from the lethal effect of an agonistic anti-Fas antibody. J. Clin. Invest., 2000, 105, 329-339.
22. Sarkar, S.; Thomas, B.; Muralikrishnan, D.; Mohanakumar, K.P. Effects of serotoninergic drugs on tremor induced by physostigmine in rats. Behav. Brain Res., 2000, 109, 187-193.
23. Haobam, R.; Sindhu, K.M.; Chandra, G.; Mohanakumar, K.P. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Behav. Brain Res., 2005, 163, 159-167.
24. Fleming, S.M.; Zhu, C.; Fernagut, P.O.; Mehta, A.; DiCarlo, C.D.; Seaman, R.L.; Chesselet, M.F. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp. Neurol., 2004, 187, 418-429.
25. Cannon, J.R.; Tapias, V.; Na, H.M.; Honick, A.S.; Drolet, R.E.; Greenamyre, J.T. A highly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis., 2009, 34, 279-290.
26. Woodlee, M.T.; Kane, J.R.; Chang, J.; Cormack, L.K.; Schallert, T. Enhanced function in the good forelimb of hemi-parkinson rats: compensatory adaptation for contralateral postural instability? Exp. Neurol., 2008, 211, 511-517.
27. Tillerson, J.L.; Miller, G.W. Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism. J. Neurosci. Methods, 2003, 123, 189-200.
28. Carlsson, T.; Winkler, C.; Lundblad, M.; Cenci, M.A.; Bjorklund, A.; Kirik, D. Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol. Dis., 2006, 21, 657-668.
29. Blandini, F.; Cova, L.; Armentero, M.T.; Zennaro, E.; Levandis, G.; Bossolasco, P.; Calzarossa, C.; Mellone, M.; Giuseppe, B.; Deliliers, G.L.; Polli, E.; Nappi, G.; Silani, V. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant., 2010, 19, 203-217.
30. Arias-Carrion, O.; Yamada, E.; Freundlieb, N.; Djufri, M.; Maurer, L.; Hermanns, G.; Ipach, B.; Chiu, W.H.; Steiner, C.; Oertel, W.H.; Höglinger, G.U. Neurogenesis in substantia nigra of parkinsonian brains? J. Neural Transm. Suppl., 2009, 279-285.
31. Arias-Carrion, O.; Verdugo-Diaz, L.; Feria-Velasco, A.; Millan-Aldaco, D.; Gutierrez, A.A.; Hernández-Cruz, A.; Drucker-Colín, R. Neurogenesis in the subventricular zone following transcranial magnetic field stimulation and nigrostriatal lesions. J. Neurosci. Res., 2004, 78, 16-28.
32. Arias-Carrion, O.; Hernandez-Lopez, S.; Ibanez-Sandoval, O.; Bargas, J.; Hernandez-Cruz, A.; Drucker-Colín, R. Neuronal precursors within the adult rat subventricular zone differentiate into dopaminergic neurons after substantia nigra lesion and chromaffin cell transplant. J. Neurosci. Res., 2006, 84, 1425-1437.
33. Salama, M.; Arias-Carrion, O. Colchicine as a promising drug for Parkinson's disease. Med. Hypotheses, 2011, 76, 150.
34. Arias-Carrion, O.; Machado, S.; Paes, F.; Velasques, B.; Teixeira, S.; Cardenas-Morales, L.; Piedade, R.; Ribeiro, P.; Nardi, A.E. Is rTMS an effective therapeutic strategy that can be used to treat Parkinson's disease? CNS Neurol. Disord. Drug Targets, 2011, 10, 693-702.
35. Rosler, T.W.; Arias-Carrion, O.; Hoglinger, G.U. Zonisamide: aspects in neuroprotection. Exp. Neurol., 2010, 224, 336-339.
36. Arias-Carrion, O.; Yuan, T.F. Autologous neural stem cell transplantation: a new treatment option for Parkinson's disease? Med. Hypotheses, 2009, 73, 757-759.
37. Carlsson, T.; Schindler, F.R.; Hollerhage, M.; Depboylu, C.; Arias-Carrion, O.; Schnurrbusch, S.; Rösler, T.W.; Wozny, W.; Schwall, G.P.; Groebe, K.; Oertel, W.H.; Brundin, P.; Schrattenholz, A.; Höglinger, G.U. Systemic administration of neuregulin-1beta1 protects dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurochem., 2011, 117, 1066-1074.
38. Arias-Carrion, O. Basic mechanisms of rTMS: Implications in Parkinson's disease. Int. Arch. Med., 2008, 1, 2.
39. Hartmann, A.; Troadec, J.D.; Hunot, S.; Kikly, K.; Faucheux, B.A.; Mouatt-Prigent, A.; Ruberg, M.; Agid, Y.; Hirsch, E.C. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J. Neurosci., 2001, 21, 2247-2255.
40. Herrup, K.; Neve, R.; Ackerman, S.L.; Copani, A. Divide and die: cell cycle events as triggers of nerve cell death. J. Neurosci., 2004, 24, 9232-9239.
41. Kimura, M.; Saji, M. Protective effect of a low dose of colchicine on the delayed cell death of hippocampal CA1 neurons following transient forebrain ischemia. Brain Res., 1997, 774, 229-233.
42. Bartels, A.L.; Willemsen, A.T.; Kortekaas, R.; de Jong, B.M.; de Vries, R.; de Klerk, O.; van Oostrom, J.C.; Portman, A.; Leenders, K.L. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J. Neural Transm., 2008, 115, 1001-1009.
43. Leibovitz, A.; Lidar, M.; Baumoehl, Y.; Livneh, A.; Segal, R. Colchicine therapy and the cognitive status of elderly patients with familial Mediterranean fever. Isr. Med. Assoc. J., 2006, 8, 469-472.
44. De Vera, M.; Rahman, M.M.; Rankin, J.; Kopec, J.; Gao, X.; Choi, H. Gout and the risk of Parkinson's disease: a cohort study. Arthritis Rheum., 2008, 59, 1549-1554.
45. Alonso, A.; Rodriguez, L.A.; Logroscino, G.; Hernan, M.A. Gout and risk of Parkinson disease: a prospective study. Neurology, 2007, 69, 1696-1700.